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Parathyroid gland responsiveness to acute hypocalcemia in dialysis
osteomalacia. The majority of chronic hemodialysis patients have
elevated serum iPTH levels and bone disease characterized by osteitis
fibrosa. However, a small group of patients develop osteomalacic bone
disease associated with normal or slightly elevated iPTH values and a
tendency to hypercalcemia which occurs either spontaneously or after
treatment with small doses of vitamin D sterols. To examine the causes
of the relatively low iPTH levels, we evaluated the change in serum
iPTH levels that occurred in response to acute hypocalcemia, produced
by dialysis using a low calcium dialysate, in II patients with osteomala-
cia and 8 control hemodialysis patients. Dialysis against a dialysate free
of calcium for 60 to 90 mm led to a fall in serum calcium to 7.5 0.2and
7.2 0.2 mg/dl in the osteomalacic and control patients, respectively.
Serum iPTH rose in controls from 1380 287 to 1960 287 pg/mI (P <
0.01), whereas in patients with osteomalacia it rose from 360 58 to 507
104 pg/mI (P < 0.05), a value only slightly above normal for this PTH
assay. These data suggest that the relatively low basal levels of serum
iPTH do not arise as a consequence of physiologic suppression of
parathyroid gland function. This reduction in parathyroid function
could contribute to the pathogenesis of low turnover osteomalacia.
Sensibilité de Ia glande parathyroIdienne a l'hypocalcemie aiguë dans
l'ostéomalacie de Ia dialyse. La majorité des malades en hemodialyse
chronique ont une élévation des concentrations d'iPTH sérique, et une
ostéopathie caractérisée par une ostéite fibreuse. Cependant, un petit
groupe de malades développe une atteinte osseuse osteomalacique
associée a des valeurs d'iPTH normales ou legerement dlevées et une
tendance a l'hypercalcemie qui survient soit spontanément, soit apres
traitment avec de petites doses de stérols vitaminiques D. Afin d'exa-
miner les raisons de ces concentrations relativement basses d'iPTH,
nous avons étudié Ia modification des concentrations seriques d'iPTH
survenant en reponse a une hypocalcémie aigue produite par une
dialyse avec un dialysat pauvre en calcium, chez 11 malades avec une
ostéomalacie, et 8 malades hCmodialyses contrOles. La dialyse contre
un dialysat sans calcium pendant 60 a 90 mm a entrainé une chute de Ia
calcémie a 7,5 0,2 et 7,2 0,2 mg/dl chez des malades ostéomalaci-
ques et contrôles, respectivement. L'iPTH sérique s'est élevée chez les
contrôles de 1380 287 a 1960 287 pg/mI (P < 0,01) tandis que chez
les malades avec une ostéomalacie elle s'est élevée de 360 58 a 507
104 pg/mI (P < 0,05), une valeur seulement légerement au-dessus de Ia
normale avec ce dosage de PTH. Ces données suggerent que les
concentrations de base relativement faibles d'iPTH sérique ne sont pas
La consequence d'une suppression physiologique du fonctionnement de
Ia glande parathyroldienne. Cette reduction du fonctionnement parathy-
roidien pourrait contribuer a Ia pathogénie de l'ostéomalacie par
renouvellement lent.
The majority of patients maintained on long-term hemodialy-
sis have elevated circulating levels of immunoreactive parathy-
roid hormone (iPTH) and develop bone disease with histologi-
cal features of osteitis fibrosa [1, 2]. However, a small fraction
of dialysis patients develop osteomalacia which may be associ-
ated with hypercalcemia occurring either spontaneously or after
treatment with small doses of vitamin D sterols [3—61. The
serum immunoreactive parathyroid hormone levels in these
patients are often only minimally elevated or even normal. This
disorder has been termed "dialysis osteomalacia."
The reason for the relatively low iPTH levels and the possible
pathogenic role for the low iPTH levels in dialysis osteomalacia
are presently unclear. Whether the low iPTH levels are due to
suppression of PTH secretion by the normal or slightly elevated
levels of serum calcium or occurs as a result of an abnormality
in parathyroid function is unknown. This study was designed to
explore this question by examining the response of the parathy-
roid glands in patients with this syndrome to acute hypocalce-
mia, the most potent stimulus to parathyroid hormone
secretion.
The results indicate that patients with dialysis osteomalacia
manifest a significantly smaller rise in parathyroid hormone
secretion during acute hypocalcemia than do other dialysis
patients. These observations suggest that the reduced basal
levels of iPTH in these patients reflect alterations in parathyroid
function, which could occur due to differences in gland size or
be secondary to altered cellular function. Further studies will be
required to delineate the precise factors that alter parathyroid
gland function in this disorder.
Methods
Studies were performed in II hemodialysis patients with
osteomalacic bone disease and in eight control patients main-
tained on regular dialysis at the Veterans Administration Wads-
worth Medical Center, Los Angeles, California. The former
patients were all referred for evaluation of severe symptomatic
bone disease, with recurrent fractures, bone pain, and disabil-
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ity. All had clinical and biochemical features similar to those
patients with "dialysis osteomalacia" previously reported [3];
several of the present patients had been included in that report.
All demonstrated evidence of aluminum accumulation. The
control hemodialysis patients were selected from the patients
undergoing hemodialysis at the Veterans Administration Wads-
worth Medical Center. They all lacked symptoms of musculo-
skeletal disease and a history of fractures; also, skeletal x-rays
were normal in all but two, who had minimal features of
subperiosteal resorption. Moreover, they had undergone hemo-
dialysis in a center with effective water treatment and dialysate
aluminum levels below 2.0 .rg/liter and where de novo cases of
"dialysis osteomalacia" have not been encountered.
All studies were performed in the dialysis unit of Veterans
Administration Wadsworth Medical Center. The protocol was
approved by the Committee on Human Research, and informed
consent was obtained from each participant before the study.
The clinical features of the patients are summarized in Table
I. The ages of 47 4 and 44 5 years in the patients with
osteomalacia and the control dialysis patients, respectively,
were not different. The osteomalacic group had a slight male
predominance, whereas the control group consisted completely
of males.
The duration of hemodialysis prior to study ranged from 3 to
9 years (mean, 5.6 years) in patients with osteornalacia and from
3 months to 10 years (mean, 3.9 years) in the control dialysis
patients. Subtotal parathyroidectomy had been performed 3 to 9
years prior to the study in seven of II osteomalacic patients
whereas all the control hemodialysis patients had intact para-
thyroid glands. Iliac crest bone biopsies, performed in the 11
patients with dialysis osteomalacia, revealed isolated osteoma-
lacia in eight, while three patients showed "patchy" osteomala-
cia; these patients showed no separation of double tetracycline
labeling and have been classified as, "aplastic osteomalacia"
[7, 8]. Bone biopsies, available in three control patients,
showed moderate osteitis fibrosa.
Five patients with osteomalacia and two control patients
were receiving l,25(OH)2D at a dose of 0.25 to 0.75 ig per day
for treatment of their hone disease. One osteomalacic patient
received 24,25(OH)2D 2.5 rg per day beginning 5 days before
the study. All vitamin D sterols were held for 24 to 48 hr prior to
study. None of the patients had liver disease, and all had daily
urine volumes less than 200 ml.
All patients were studied in the fasting state. Baseline plasma
samples were obtained for the determination of total and
ionized calcium, phosphorus, magnesium, albumin, total pro-
tein, and immunoreactive parathyroid hormone. Hemodialysis
was then initiated using calcium-free dialysate containing, in
mEq/liter: Na, 135; K, 2.0; Cl, 102; and acetate, 35. Dialysis
using a calcium-free dialysate was continued for 90 mm in all
but two of the control and two of the osteomalacic patients. In
these individuals the calcium-free dialysate was terminated at
60 mm because of symptoms of hypocalcemia. Calcium, 2.2
mEq/liter, was then added to the dialysate and dialysis was
continued for 120 to 150 mm. Blood was obtained from the
arterial line of the dialyzer at intervals of 30 mm throughout the
study for determination of total calcium, phosphorus, and
iPTH. Blood pressure was measured at intervals of 5 to 10 mm
using a Dinamap (Crikiton Inc., Tampa, Florida). Body weight
was recorded using an automatic bed scale. Dialyzers used
included 1.36 m2 parallel plate (AB Gambro, Lund, Sweden)
and hollow fiber, 1.2 m2 (Travenol Laboratories, Inc., Deer-
field, Illinois).
Analytical methods. Total calcium was determined by EGTA
titration utilizing the Automatic Calcium Analyzer (Calcette,
Precision Scientific Group, Chicago, Illinois). Phosphorus was
measured using the malachite green micromethod. Magnesium
was determined using atomic absorption spectrometry. Ionized
calcium was determined using a flow-through electrode (Orion
Research, Cambridge, Massachusetts). Immunoreactive para-
thyroid hormone was determined by radioimmunoassay using
methods described previously [9]. The antisera used was
AS211/41 (Burroughs Weilcome Laboratories, London, En-
gland); this antiserum is polyvalent but reacts primarily with the
N-terminal of the PTH molecule. Normal values for this assay
are below 500 pg/mI, and the lower limits for detection are 150
pg/mI. Aluminum content of bone was measured in a sample of
trabecular bone from ten patients with osteomalacia using
flameless atomic absorption spectrometry as described previ-
ously [10].
Results are expressed as mean I SEM. Comparison of
results between experimental periods and between groups were
made using paired or unpaired Student's t test and x2 analysis as
necessary.
Results
Baseline serum biochemical values are shown in Table 2.
Both total and ionized calcium were higher in the patients with
osteomalacia than in controls, 10.0 0.4 compared to 9.0 0.2
mg/dl, and 4.9 0.2 compared to 4.2 0.1 mg/dl, respectively(P < 0.01). Four of the osteomalacic patients had serum
calcium values greater than 10.5 ing/dI, the upper limit of
normal. Serum magnesium was also slightly but significantly
higher in osteomalacic patients, 2.7 0.1 compared to 2.1 0.1
mg/dl (P < 0.05). Immunoreactive PTH was increased marked-
ly in control hemodialysis patients, 1380 258 pg/ml; whereas
it was within the normal range in the osteomalacia patients, 361
58 pg/mI. Serum phosphorus concentrations were not signifi-
cantly different in the two groups.
Figure 1 depicts the effects of dialysis with a calcium-free
dialysate followed by dialysate containing calcium, 2.2 mEq-
/liter, on serum calcium. Dialysis using a calcium-free dialysate
for 90 mm led to a significant fall in mean total serum calcium to
7.5 and 7.3 mg/dl in the osteomalacic and control hemodialysis
Table 1. Clinical features and findings of bone biopsy
Dialysis Control
osteomalacia hemodialysisGroup
Age, years
Male/Female
Duration of dialysis, years
Subtotal PTX
Bone histology
OF
Aplastic OM
OM
47
6/5
5.6 0.5"
8
0
3
8
44
8/0
3.9 1.3"
0
3
Abbreviations: PTX, parathyroidectomy; OF, osteitis fibrosa; OM,
osteomalacia
Means SEM.
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Control
Osteomalacia hemodialysis
Ca, mgldi 10.0 0.3 9.0 0.2'
P. mg/dl 5.2 0.4 5.1 0.6
Mg, mg/dl 2.7 0.1" 2.1 0.1
Alk P'tase, lU/liter 166 20 107 20
iPTH, pg/mi 360 58 1380 258"
0 60 90 120 180 210
Time, minutes
Fig. 1. Serum calcium levels during dialysis using a low calcium
dialysate in control hemodialysis (HD) patients (open circles) and
patients with osteomalacia (closed circles). Data are means SEM. The
asterisk represents P < 0.05.
patients, respectively. The subsequent addition of calcium, 2.2
mEq/liter to the dialysate resulted in stabilization of total serum
calcium at levels near 8 mg/dl.
Figure 2 depicts the change in iPTH at 90 and 180 mm of
study. By 90 mm, when serum calcium reached its nadir,
control dialysis patients manifested a rise in serum iPTH from
1380 258 to 1960 287 pg/mI (P < 0.01). By contrast,
exposure of the osteomalacic patients to an identical degree of
hypocalcemia resulted in only a small although significant, rise
in iPTH from 361 58 to 507 104 pg/mi (P < 0.05), a value
just slightly above the normal level for this assay. By 180 mm,
despite continuing hypocaicemia, iPTH levels in both groups
had decreased and were not significantly different from base-
line. Moreover, as depicted in Figure 3, the increment in serum
iPTH at both 90 and 180 mm was lower in the osteomalacic
patients than in controls.
The osteomalacic patients were subdivided further into a
group who had undergone parathyroidectomy and those with
intact glands to examine whether prior parathyroidectomy may
have affected the parathyroid gland responsiveness. As illus-
trated in Figure 2, all patients with intact glands manifested a
rise in iPTH greater than 100 pg/mI. In contrast, most patients
who had undergone parathyroidectomy showed no change in
Time, minutes
Fig. 2. Serum iPTH levels before and at 90 and 180 mm of hypocalcemic
dialysis in control hemodialysis patients (left panel) and in patients with
osteomalacia (right panel). Patients with osteomalacia are subdivided
into those with intact glands (closed triangles) and those with an earlier
history of subtotal parathyroidectomy (closed circles). Each symbol
represents an individual patient.
iPTH at all, and only one person who had undergone parathy-
roidectomy showed an increase in iPTH of more than 100 pg/mi.
Thus, the fraction of osteomalacic patients having had parathy-
roidectomy who exhibited a rise in iPTH greater than 100 pg/mi
was lower than those with intact parathyroid glands, P < 0.05,
by x2 analysis. However, the osteomalacic patients with intact
parathyroid glands still manifested a smaller absolute rise in
iPTH at 90 mm than did control patients, 274 93 and 579 68
pg/ml, respectively (P < 0.05).
Figure 4 depicts the relationship between individual values of
iPTH and total serum calcium for the osteomalacic and control
patients. The levels of iPTH were lower in the patients with
osteomalacia than in control hemodialysis patients at all levels
of serum calcium.
The accumulation of aluminum in bone has been suggested as
a pathogenic factor in osteomalacia [11]. Moreover, aluminum
also accumulates in parathyroid glands 1121, and, theoretically,
it could affect parathyroid gland function. If this were so, one
might anticipate that individuals with the greatest aluminum
burden might show more impairment of PTH secretion. Howe v-
er, as illustrated in Figure 5, there was no relationship between
changes in iPTH levels and aluminum burden, as indicated by
bone aluminum concentrations.
Discussion
The results of this study indicate that the relatively low serum
iPTH values observed in dialysis patients with osteomalacia
arise due to alterations in parathyroid function and do not occur
because of simple suppression by the prevailing level of blood
calcium. This conclusion is based on the demonstration that
dialysis-induced hypocalcemia elicited a significantly smaller
rise in serum iPTH levels in patients with osteomalacia than in
"control hemodialysis" patients. Moreover, the larger incre-
ment in serum iPTH occurred in the control hemodialysis
patients despite the lower baseline serum calcium levels; in-
deed, the baseline serum calcium levels were below 8.5 mg/dl in
three control patients, a level that is lower than that at which
the greatest increment in PTH secretion might occur during
Table 2. Baseline biochemical featuresa 3500
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acute hypocalcemia [131. By contrast, serum calcium fell from
10 to less than 8 mg/dl in the osteomalacic patients, a range over
which the sharpest increment in IPTH secretion might be
expected.
It could be argued that hypocalcemia of longer duration might
be necessary to stimulate PTH secretion. The observation that
serum iPTH fell between 90 to 180 mm despite continued
hypocalcemia in the control dialysis patients suggests that PTH
is secreted rapidly in response to hypocalcemia in the second-
ary hyperparathyroidism of uremia. Studies in nonuremic ani-
mals also suggest that PTH secretion occurs rapidly but is not
sustained despite persistent hypocalcemia [14]. Thus, it seems
unlikely that a longer duration of hypocalcemia would have
elicited any greater increment in serum iPTH in the patients
with osteomalacia. A comment regarding our interpretation of
the changes in serum iPTH levels is due. The absolute incre-
ment in iPTH was lower in the osteomalacia patients; however,
the percent increase in serum iPTH in the groups was similar,
approximately 40% in both. The msjority of iPTH values in the
osteomalacia patients were near the lower limits of detection for
this assay; thus, there is less confidence in the small changes in
iPTH noted. It is for this reason that we believe that comparison
of the absolute change in iPTH is more meaningful than the
percentage increase. Unfortunately, the response of normal
humans, who have baseline iPTH levels similar to the osteoma-
lacia patients to the hypocalcemic stress, was not evaluated in
this study. In previous studies of normal subjects, serum iPTH
rose by at least fourfold above control values in response to
hypocalcemia induced by the infusion of EDTA [15]; thus the
attenuated response in the osteomalacia patients is even more
striking. Furthermore, it could be argued that a proportionally
greater increase in serum iPTH might be expected, if the lower
baseline iPTH levels in the osteomalacia patients occurred due
to suppression by hypercalcemia.
Approximately 60% of the patients with osteomalacia had
A
.0Normal level A A* •k
12 10 8 6
Serum calcium, mg/d/
Fig. 4. Relationship between individual values of serum iPTH and
serum calcium in control hemodialysis patients (open circles) in pa-
tients with osteomalacia and intact parathyroid glands (closed trian
gles) and those with osteomalacia and a history of subtotal parathyroid-
ectomy (closed circles) during hvpocalcemic dialysis. The two inter-
rupted lines denote the upper limits of normal and lower limits of
detection, respectively, for the PT H assay.
undergone prior subtotal parathyroid resection: indeed, these
patients did show a smaller increment in serum iPTH than did
the osetomalacia patients without prior parathyroid surgery.
However, there was no evidence of surgical total hypoparathy-
roidism in any of these patients, as evidenced by prolonged
hypocalcemia or a need for vitamin D therapy to maintain a
normal serum calcium. Thus, there was little evidence for total
parathyroid removal in these patients although the surgical
reduction in gland mass may have contributed to the reduced
response.
These studies do not provide evidence regarding the cause of
the reduced release of PTH in response to hypocalcemia. The
differences in PTH secretion in response to hypocalcemia could
arise due to differences in gland size, due to an intrinsic change
in the parathyroid cells, that is, a shift in the "set point" or the
calcium levels at which the PTH secretion by the cell is altered
[16], or a combination of both factors. The present observations
do not allow us to differentiate between these possibilities.
Although several of the osteomalacic patients had received
vitamin D sterols for treatment of bone disease prior to study,
there was no difference in the response to hypocalcemia in
those who received vitamin D compared to those who did not.
Recently a high level of aluminum was shown to occur in the
bones of uremic patients with osteomalacia [17]. Also, a possi-
ble pathogenic role for aluminum accumulation has been pro-
posed [18, 19]. Studies of parathyroid glands obtained from
hyperparathyroid and normal humans and from rats also
showed preferential accumulation of aluminum in parathyroid
glands [12]. Furthermore, a recent in vitro study demonstrated
that high concentrations of aluminum can inhibit PTH secretion
in cell culture [20]. Thus, it is conceivable that aluminum
accumulation impairs parathyroid hormone secretion.
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Fig. 3. Changes in iPTH (A) at 90 and 180 mm in osteomalacic patients
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Fig. 5. Relationship between bone aluminum Content and the maximal
rise in serum iPTH in patients with osteomalacia. Each closed circle
represents a separate patient.
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